ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

June 22, 2021

Delegates from the Association for Clinical Oncology (ASCO) participated in a Special Meeting of the American Medical Association’s (AMA) House of Delegates (HOD), where the HOD voted to approve two ASCO-backed resolutions.

June 22, 2021

In a joint position statement, ASCO and Friends of Cancer Research say individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion.

June 17, 2021

The U.S. Department of Health and Human Services (HHS) released revised reporting requirements for recipients of Provider Relief Fund (PRF) payments. Updates include expanding the amount of time providers will have to report information, efforts to reduce burdens on smaller providers, and extending key deadlines for expending PRF payments for recipients who received payments after June 30, 2020.

June 16, 2021

A new ASCO guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, including radiation. The recommendations update the 2020 guideline from ASCO, the American Society for Radiation Oncology (ASTRO), and the Society of Surgical Oncology (SSO) published on the management of hereditary breast cancer.

June 8, 2021

The COVID-19 pandemic has profoundly interrupted delivery of key preventive services, resulting in many adolescents missing routine human papillomavirus (HPV) vaccine doses. In response, the American Society of Clinical Oncology (ASCO) and nearly 80 National Cancer Institute (NCI)-designated cancer centers and other organizations issued a joint statement urging the nation’s health care systems, physicians, parents and children, and young adults to get HPV vaccination back on track.

June 8, 2021

The American Society of Clinical Oncology (ASCO) issued a new position statement outlining the issues that telemedicine cross-state licensure presents for the cancer care community, in addition to ASCO’s recommendations to continue the practice during the COVID-19 pandemic and beyond.

June 7, 2021

American Society of Clinical Oncology (ASCO) members who are practicing oncologists may have received emails inviting them to participate in the American Medical Association’s (AMA) Specialty Society Relative Value Scale (RVS) Update Committee (RUC) survey. This important survey will help ASCO, in collaboration with the RUC, recommend relative value units and direct practice expense values to the Centers for Medicare & Medicaid Services (CMS) for certain services.

June 2, 2021

On Friday, May 28, President Biden released his full Fiscal Year (FY) 2022 budget request, which expands on the ‘skinny’ budget released in early April 2021. The full budget request includes an increase in funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and would fully fund the 21st Century Cures Act and the Beau Biden Cancer Moonshot Initiative. While the budget request is non-binding, it does signal the President’s priorities to Congress, stakeholders, and the general public.

May 26, 2021

A recording is now available of a virtual roundtable focused on achieving equity in precision cancer care. The event was hosted by the American Society of Clinical Oncology (ASCO).

May 25, 2021

“The Association for Clinical Oncology (ASCO) congratulates Chiquita Brooks-LaSure on her confirmation as Administrator of the Centers for Medicare & Medicaid Services (CMS). Administrator Brooks-LaSure is now in a key position to lead CMS during the agency’s continued response to the COVID-19 pandemic and the evolving implementation of the Affordable Care Act (ACA) under the new Administration.

May 25, 2021

ASCO has been notified of a recent safety notice relating to the drug BLINCYTO® (blinatumomab) under the Food and Drug Administration’s (FDA) Risk Evaluation and Mitigation Strategy (REMS) program. A REMS Letter for Professional Societies has been released to address the potential risks for (1) cytokine release syndrome (CRS), which may be life-threatening or fatal, (2) neurological toxicities, which may be severe, life-threatening, or fatal, and (3) preparation and administration errors associated with use of BLINCYTO®.

May 25, 2021

The Centers for Medicare & Medicaid Services (CMS) recently announced updates to the Merit-based Incentive Payment System (MIPS) under the Quality Payment Program (QPP). The agency reweighted the 2020 MIPS cost performance category, opened applications for the 2021 MIPS promoting interoperability performance category hardship and extreme and uncontrollable circumstances exceptions, and released MIPS Cost measure benchmarks. 

May 25, 2021

The Association for Clinical Oncology (ASCO) is calling on Congress to continue their bipartisan support of federally funded research. Robust, sustained, and predictable funding growth for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) baseline budgets are critical in advancing our nation’s work towards combating, and ultimately curing, diseases like cancer.

May 21, 2021

The Improving Senior’s Timely Access to Care Act (H.R. 3173) was recently re-introduced in the U.S. House of Representatives by Reps. Suzan DelBene (WA), Mike Kelly (PA), Dr. Ami Bera (CA), and Larry Bucshon (IN). The bill aims to streamline prior authorization practices and reduce care delays within the Medicare Advantage (MA) program.

May 21, 2021

On May 21, 2021, the Food and Drug Administration granted accelerated approval to amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Pages